Treatment of Hepatorenal Syndrome
The first-line treatment for hepatorenal syndrome is terlipressin plus albumin, which has a response rate of 40-50% in patients with HRS Type 1. 1
Diagnostic Criteria
Before initiating treatment, confirm the diagnosis of hepatorenal syndrome:
- Increased serum creatinine (>133 μmol/L or 1.5 mg/dL)
- Exclusion of other causes of renal failure
- Perform diagnostic paracentesis with SAAG calculation
- Abdominal and renal ultrasound to confirm cirrhosis, assess portal hypertension, and rule out obstructive uropathy 1
Treatment Algorithm
First-Line Treatment: Terlipressin plus Albumin
- Dosing regimen:
- Terlipressin: Start at 1 mg IV every 4-6 hours
- Increase to maximum 2 mg every 4-6 hours if serum creatinine does not decrease by at least 25% after 3 days
- Albumin: 1 g/kg on day 1, followed by 20-40 g/day 1
- Important limitation: Patients with serum creatinine >5 mg/dL are unlikely to experience benefit 2
- Predictors of favorable response:
- Serum bilirubin <10 mg/dL before treatment
- Increase in mean arterial pressure >5 mm Hg at day 3 of treatment
- Lower baseline serum creatinine (<5.0 mg/dL) 1
Alternative Treatments
- Norepinephrine plus albumin (in ICU setting) 1
- Midodrine + octreotide + albumin 1
- Midodrine: Titrate up to 12.5 mg orally three times daily
- Octreotide: 200 μg subcutaneously three times daily
- Albumin: 10-20 g/day IV for up to 20 days
- Note: This regimen can be administered outside the ICU and even at home 1
Monitoring and Complications
- Monitor serum creatinine, mean arterial pressure, and cardiovascular status
- Cardiovascular complications occur in approximately 12% of patients treated with terlipressin 1
- Recurrence after withdrawal of terlipressin therapy is uncommon, and retreatment is generally effective 1
Prevention Strategies
- Norfloxacin (400 mg/day) reduces the incidence of HRS in advanced cirrhosis 1
- Pentoxifylline (400 mg three times daily) may prevent HRS development in severe alcoholic hepatitis 1
- Treatment of spontaneous bacterial peritonitis with albumin plus antibiotics reduces the risk of HRS development 1
Definitive Treatment
- Liver transplantation is the only curative treatment for HRS 1
- Expedited referral for transplantation should be considered for all patients with cirrhosis, ascites, and HRS
- Simultaneous liver-kidney transplantation should be considered for patients with significant kidney damage 1
Bridge Therapies
- Continuous renal replacement therapy (RRT) may be used as a bridge to liver transplantation in non-responders to vasoconstrictors 1
- Transjugular Intrahepatic Portosystemic Shunt (TIPS) may be considered in selected patients with partial response to medical therapy, but is contraindicated in severe liver failure or significant encephalopathy 1
Prognosis
Despite treatment, the prognosis for HRS patients remains poor, with a median survival of approximately 3 months for all HRS patients. Untreated Type 1 HRS has a median survival of approximately 1 month, emphasizing the importance of early diagnosis and treatment 1.